Search clinical trials for: EGFR TKIs (gefitinib, erlotinib, afatinib, et al)

Total 39 results

Samsung Medical Center
AstraZeneca

Unknown

Evaluation of EGFR TKI Resistance Mechanism Using Plasma DNA Analysis

EGFR Mutation Positive Non-small Cell Lung Cancer

Korea, Republic of
Sichuan Cancer Hospital and Research Institute
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Apatinib in the Treatment of Patients With EGFR T790M-Negative NSCLC

Neoplasms | Respiratory Tract Diseases | Lung Diseases | Thoracic Neoplasms | Non-Small-Cell Lung

China
Peking University Third Hospital

Unknown

Apatinib Combine With EGFR-TKI for Advanced EGFR-TKI-resistant Non-Small Cell Lung Cancer

Nonsmall Cell Lung Cancer

China
China Medical University, China
General Hospital of Shenyang Military Region; Shengjing Hospital; Liaoning Tumor... and other collaborators

Unknown

β-elemene Combine With EGFR-TKI for Advanced EGFR-TKI-resistant NSCLC

Non Small Cell Lung Cancer
Peking University
Hangzhou DIAN Medical Diagnostic Center Co., Ltd., China

Recruiting

Targeted Agent Evaluation in Digestive Cancers in China Based on Molecular Characteristics (VISIONARY)

Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Gastrointestinal Stromal Tumors | Neuroendocrine Tumors | Esophageal Squamous Cell Carcinoma | Biliary Tract Neoplasms | Unknown Primary Cancer | Digestive Cancer

China
Zhejiang Cancer Hospital

Unknown

Prophylactic Cranial Irradiation in Erlotinib/Gefitinib-responders With Non-small Cell Lung Cancer (NSCLC) (RT1001)

Non-small Cell Lung Cancer

China
First People's Hospital of Hangzhou

Unknown

A Study of Hypofractionated Radiotherapy for Limited Metastatic NSCLC Harboring Sensitizing EGFR Mutations After First Line TKI Therapy

Lung Adenocarcinoma | EGFR Positive Non-small Cell Lung Cancer
Tian Xie
LinkDoc Technology (Beijing) Co. Ltd.

Recruiting

Synergistic Effect of Elemene Plus TKIs Compared With TKIs in EGFR-mutated Advanced NSCLC：Prospective Study (SELECT-2)

Adenocarcinoma | Carcinoma | Non-Small-Cell Lung Cancer

China
Instituto Nacional de Cancerologia de Mexico

Unknown

Metformin Plus TKI Use in Patients With Non-Small Cell Lung Carcinoma

EGFR Gene Mutation | Tyrosine Kinase Mutation | Non-Small Cell Adenocarcinoma

Mexico
China Medical University Hospital

Not yet recruiting

Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer Patients

Non-small Cell Lung Cancer | EGFR Gene Mutation | EGFR-TKI Resistant Mutation
Shanghai Zhongshan Hospital

Not yet recruiting

Camrelizumab in Patients With Unresectable Hepatocellular Carcinoma

Unresectable Hepatocellular Carcinoma
Boehringer Ingelheim

Completed

The Study Observes How Long Patients With Non-small Cell Lung Cancer (NSCLC) Benefit From Treatment With Epidermal Growth Factor Tyrosine Kinase Inhibitor (EGFR-TKI) When Given Either for Uncommon Mutations or for Common Mutations in the Sequence Afatinib Followed by Osimertinib (UpSwinG)

Non-squamous, Non-Small Cell Lung Cancer

United Kingdom
Sichuan Provincial People's Hospital

Unknown

Hypofractionated Brain Radiation In EGFR Mutated Adenocarcinoma Cranial Disease (Hybrid) (Hybrid)

Stage IV EGFR Mutated NSCL With Brain Metastases

China
Nanfang Hospital of Southern Medical University

Unknown

Observation of the Effect of Chemotherapy Combined With Tyrosinase Inhibitor on the Reactivation of CMV and EBV in Patients With Acute Lymphoblastic Leukemia

Leukemia, Lymphoblastic, Acute

China
Shanghai Pulmonary Hospital, Shanghai, China

Unknown

EGFR-TKI With/Without Chemotherapy in NSCLC Patients With Both EGFR Mutation and BIM Deletion Polymorphism

Nonsmall Cell Lung Cancer | EGFR Gene Mutation
Oslo University Hospital
The Research Council of Norway

Completed

N-of-1 Trial: Actionable Target Identification in Metastatic Cancer for Palliative Systemic Therapy (MetAction)

Metastatic Cancer

Norway
Shanghai Chest Hospital
Changhai Hospital; Ruijin Hospital

Unknown

Chemotherapy Plus Gefitinib for Advanced Lung Adenocarcinoma and Sensitive EGFR Mutations: a Randomized Controlled Trial

Lung Adenocarcinoma
Sun Yat-sen University

Unknown

EGFR-TKI Concurrent With/Without WBRT in Brain Metastasis From NSCLC

Non-Small Cell Lung Cancer

China
SciClone Pharmaceuticals

Unknown

First Line Bio-immunotherapy With Thymosin Alpha 1 in Patients With Sensitizing EGFR Mutation Positive Non Small Cell Lung Cancer Who Are Taking Standard of Care Therapy

EGFR Mutation Positive Non Small Cell Lung Cancer

Italy
Beijing Chest Hospital

Unknown

The Efficacy and Drug Resistance Molecular Biology of Apatinib Combined With EGFR-TK1 Treated for Advanced Slow-progressed Non-Small Cell Lung Cancer (NSCLC)

Non Small Cell Lung Cancer

China
Second Affiliated Hospital of Guangzhou Medical...
Sun Yat-sen University; The First Affiliated Hospital of Guangzhou Medical...

Recruiting

iCAGES-guided Precision Therapy for Cancers in Contrast to Standard Care or IHC-guided Theray

Cancer | Lung Cancer | Gene Product Sequence Variation | Gene Abnormality

China
Sichuan Provincial People's Hospital

Terminated

Stereotactic Body Radiation Therapy (SBRT) in Newly Diagnosed Advanced Staged Lung Adenocarcinoma (Sindas) (Sindas)

Stage IV EGFR Mutated Non-Small Cell Lung Cancer

China
Sun Yat-sen University

Unknown

A Pilot Study of Genomic Sequencing Guided Individualized Therapy in Gastrointestinal Cancers, GITIC Study (GITIC)

Gastrointestinal Cancers

China
Medical College of Wisconsin
Memorial Sloan Kettering Cancer Center; Dana-Farber Cancer Institute; University... and other collaborators

Completed

The Life After Stopping Tyrosine Kinase Inhibitors Study (The LAST Study)

Leukemia, Myeloid, Chronic

United States
Fudan University

Recruiting

Camrelizumab Combined With Apatinib in the Treatment of Advanced Sarcomatoid Carcinoma or Carcinosarcoma

Carcinosarcoma | Sarcomatoid Carcinoma | PD-1 Immunotherapy | VEGFR-TKI

China
Pfizer

Recruiting

A Study to Learn About the Effectiveness of Cancer Medicines in Patients With Metastatic Non-small Cell Lung Cancer in Norway. (DELINOR)

Non-Small Cell Lung Cancer

Norway
Shenzhen People's Hospital

Unknown

Apatinib Combined With EGFR-TKI for Advanced Slow-progressed EGFR-TKI Resistant NSCLC (AFLC)

NSCLC | Apatinib | EGFR-TKI

China
Shanghai University of Traditional Chinese Medicine
Shanghai Chest Hospital

Unknown

Efficacy Study of Chinese Medicine Plus EGFR-TKI Versus EGFR-TKI in Advanced Pulmonary Adenocarcinoma

Cancer
First People's Hospital of Hangzhou

Unknown

Radiotherapy Combined With Thymosin for Metastatic NSCLC Patients Who Showed Stable Disease After First Line TKI Therapy

Lung Adenocarcinoma

China
Tianjin Medical University Cancer Institute and...

Unknown

Erlotinib Concurrent With Radiation Therapy in Non-small-cell Lung Cancer

Carcinoma, Non-Small Cell Lung

China
CStone Pharmaceuticals

Recruiting

Safety and Efficacy of Avapritinib in Chinese Patients With Gastrointestinal Stromal Tumor (GIST) in the Real World

Gastrointestinal Stromal Tumors

China
Guangdong Association of Clinical Trials

Recruiting

Bevacizumab Plus EGFR-TKIs in Chinese Patients With EGFR-mutant NSCLC: a Real-world Study (BELLA)

NSCLC

China
Milton S. Hershey Medical Center

Terminated

Omega -3 Fatty Acid in Combination With Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia

Chronic Myeloid Leukemia, Chronic Phase

United States
Cancer Institute and Hospital, Chinese Academy...

Not yet recruiting

RC48 Combined With EGFR or HER2 TKI for Locally Advanced or Metastatic NSCLC Patients With HER2 Alterations

Non Small Cell Lung Cancer | ERBB2 Mutation-Related Tumors | Disitamab Vedotin | ERBB2 Gene Duplication
Shanghai Pulmonary Hospital, Shanghai, China

Unknown

EGFR-TKI With Chemotherapy in NSCLC Patients With Both EGFR Mutation and BIM Deletion Polymorphism

Non-Small-Cell Lung Cancer
Baodong Qin

Recruiting

Efficacy and Safety of Precision Therapy in Refractory Tumor

Refractory Tumor | Rare Tumor

China
Sungkyunkwan University
Ministry of Food and Drug Safety, Korea

Unknown

PD-1 Immune Checkpoint Inhibitors and Immune-Related Adverse Events: a Cohort Study

Carcinoma, Non-Small-Cell Lung | Immune-Related Adverse Events
Institut National de la Santé Et de la Recherche...
Institut Bergonié; Commissariat A L'energie Atomique; Plateforme labellisée Inca... and other collaborators

Active, not recruiting

Molecular Profiling of Advanced Soft-tissue Sarcomas (MULTISARC)

Soft Tissue Sarcoma

France
OHSU Knight Cancer Institute
Oregon Health and Science University

Terminated

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Primary Myelofibrosis | Anemia | Recurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Anatomic Stage IV Breast Cancer AJCC v8 | Recurrent Acute Myeloid Leukemia | Recurrent Myelodysplastic Syndrome | Refractory Acute Myeloid Leukemia | Refractory Chronic Myelomonocytic Leukemia | Refractory Myelodysplastic... and other conditions

United States

Search clinical trials for: EGFR TKIs (gefitinib, erlotinib, afatinib, et al)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Slovakia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations